ABVC BioPharma, Inc. (NASDAQ: ABVC) announced today that its oncology partner OncoX BioPharma, Inc. has completed a $100,000 licensing payment under their existing agreement. This is the fifth licensing payment made by OncoX in 2025, bringing total payments to $695,950. The transaction advances ABVC's multi-partner licensing strategy and its oncology revenue framework, highlighting the company's transition from a traditional research-focused entity to an asset-light, cash-visible international licensing platform.
OncoX BioPharma, a U.S.-based biotechnology company specializing in plant-derived oncology therapeutics, is developing a lead candidate from Grifola frondosa (maitake mushroom) extract. This candidate has shown potential in treating triple-negative breast cancer, non-small-cell lung cancer, pancreatic cancer, and myelodysplastic syndrome (MDS). OncoX also collaborates with Japanese biomedical companies and academic institutions on Precision Gene-Oriented Therapies and Anti-Fibrosis Technologies, combining stem-cell and immunotherapy platforms to accelerate clinical validation and expand global applications. These collaborations form a growing biotechnology network connecting the U.S. and Asian markets.
ABVC's three-tier value-amplification model provides a clear time horizon for value creation. In the short term (0-12 months), licensing payments totaling $695,950 demonstrate cash-flow visibility and consistent milestone execution. In the long term (24+ months), ABVC is eligible for a 5% royalty on net sales up to a cumulative $55 million, creating a sustainable, high-profit-margin, recurring income stream. This model aims to transition ABVC into an asset-light, cash-visible international licensing platform with scalable and more predictable returns.
Based on consolidated data across all licensing partners, ABVC's total contractual cash revenue pool has the potential to reach up to $14.25 million, with $2.14 million received as of October 2025. Dr. Uttam Patil, ABVC's Chief Executive Officer, stated: "The continued licensing payments from OncoX reflect the progress and execution of our partnership strategy. This collaboration illustrates the effectiveness of ABVC's licensing-driven business model in transforming R&D assets into recurring value creation for both investors and patients."
OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies derived from natural sources. The company has three proprietary pipeline programs, including its lead product candidate targeting solid tumors and hematologic malignancies, which has demonstrated promising safety and efficacy in early-phase clinical studies and has received four INDs approved by the U.S. FDA. OncoX is also expanding into cancer-supportive care and preventative health through proprietary natural ingredients, having acquired the Lycogen® extraction platform to enter fields such as preventative medicine, chronic disease care, aesthetic medicine, and animal health. These cross-sector applications are projected to reach a global market size of $187 million by 2030, according to Allied Market Research (source). OncoX operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA-registered facility, and seeks to expand its global footprint in the United States, Japan, Taiwan, and other Asia-Pacific markets.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from its network of world-renowned research institutions, including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center, to conduct proof-of-concept trials through Phase II of clinical development.
